Wegovy is Being Tested to Treat Severe Fatty Liver Disease

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NASH), affects nearly one-third of the US population (over 100 million people). Obesity is thought to be the most common cause. In some cases, MASLD can develop into a more serious condition called metabolic dysfunction-associated steatohepatitis (MASH). Both conditions develop when the liver […]

Can GLP-1s Help Prevent Glaucoma?

A new study by ophthalmologists suggests that drugs based on GLP-1 receptor agonists (GLP-1RAs), like Wegovy, Mounjaro, Saxenda, Rybelsus, and Ozempic, which were originally designed to control blood sugar levels in people with type 2 diabetes, may also protect against a number of eye conditions. Research into the use of GLP-1 drugs for glaucoma found […]

GLP-1s Join the Fight Against Addiction

At this year’s American Society of Addiction Medicine (ASAM) Annual Conference, a big focus was on GLP-1 receptor agonists (GLP-1 RAs). These drugs, commonly used to treat diabetes, have also been found to aid in weight loss, leading to their consideration as a treatment for obesity. However, GLP-1s aren’t just for weight loss or type […]

New Hope for Lowering the Risk of Dementia

Just this week, I was asked by a colleague to comment on a fairly technical article, and I was struck by the exact wording used in its opening question: Are cardioprotective glucose-lowering agents associated with reduced risk of dementia? I spend a fair bit of time reviewing and replying to questions and requests from our […]

Breakthrough Study Links GLP-1 to Reduced Alcohol Dependence

Researchers have been exploring whether glucagon-like peptide-1 receptor (GLP-1) agonists, such as semaglutide and liraglutide, could help treat alcohol use disorder (AUD). A long-term study with over 8 years of follow-up found that people using these drugs had a significantly lower risk of hospitalization for AUD compared to those on officially approved AUD treatments. This […]

The Truth: Diet and Exercise Vs. Obesity Medication

If there’s still some doubt in your mind about whether you can lose more weight with a simple diet and exercise program than you can with the highly popular new weight-loss medicines, then you should pay some attention to the following quote that puts this issue to rest once and for all. According to Dr. […]

Are Your Kidneys OK?

The human body can manage with reduced kidney function for a long time, often without showing any signs. This is why World Kidney Day 2025’s theme is, Are Your Kidneys OK? Detect early and protect kidney health. While chronic kidney disease has no cure, if it is caught early enough, measures can be taken to […]

News: Zepbound (tirzepatide) Approved to Treat Obstructive Sleep Apnea

The weight-loss drug Zepbound is the first FDA-approved prescription medicine to help treat obstructive sleep apnea (OSA). Zepbound, or tirzepatide, originally received approval in November 2023 to treat obesity. It’s now a new rival to Novo Nordisk’s popular drug, Wegovy. The FDA has now given the green light for tirzepatide to treat obstructive sleep apnea […]

Improve GLP-1 Weight Loss With Healthy Weight Pack

The weight loss effects of glucagon-like peptide-1 (GLP-1) medications like Wegovy are well known. In studies, patients taking a 2.4-mg dose of semaglutide, the active ingredient in Wegovy, lost about 6% of their body weight in 12 weeks and 12% in 28 weeks. Combining targeted ingredients like those provided by the Healthy Weight Pack with GLP-1 can […]

Semaglutide Has Done it Again for Knee Osteoarthritis

Drug trials involving human test subjects always involve some level of dropout. Dropout refers to how many subjects stopped participating before the planned end date – for any reason. In most instances, the level of dropout has negative connotations because it means that the subjects were either experiencing intolerable side effects or were not sticking […]